HOME Top Market Reports Neuromodulation Market – [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS) & Transcranial Magnetic Stimulation (TMS)] – Forecasts to 2017

Neuromodulation Market – [Spinal Cord Stimulation (SCS), Vagus Nerve Stimulation (VNS), Gastric Electrical Stimulation (GES), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS) & Transcranial Magnetic Stimulation (TMS)] – Forecasts to 2017

By: marketsandmarkets.com
Publishing Date: January 2013
Report Code: MD 1378

Discount on Reports  

Enquiry Before Buying
Analyst Briefing  
purchase report
download pdf  request for customisation


Neuromodulation devices have emerged as one of the fastest growing segments of the medical device market due to high demand for minimally invasive and non–invasive treatment. With advancements in technology, neuromodulation is expected to become a promising therapeutic area and high growth industry in the next decade, as it offers symptomatic relief mainly from chronic pain, incontinence, heart failure, headache, depression, epilepsy, etc. The neuromodulation devices market includes deep brain stimulation, spinal cord stimulation, vagus nerve stimulation, sacral nerve stimulation and others external stimulation devices such as transcranial magnetic stimulation, and transcutaneous electrical nerve stimulation (TENS).

The neuromodulation technique acts directly upon nerves or the target area where the activity of nerves is altered due to biological responses produced by electrical stimulation or drug infusion. These devices include small electrodes that are attached to the brain, the spinal cord, or peripheral nerves. These precisely placed leads are connected by means of an extension cable to a pulse generator to generate electrical stimulation. Neuromodulation can have applications in any area of the body and can treat several diseases like chronic pain, epilepsy, psychiatric disorder, movement disorder, cardiovascular disorder, genitourinary and colorectal disorder, stroke and brain injury, and gastric disorder.

The main drivers for the neuromodulation market are the rising population of aged people and age-related diseases like Alzheimer’s, epilepsy, spinal cord injury, and Parkinson’s disease. According to the International Neuromodulation Society, about 40 million to 50 million patients worldwide suffer from epilepsy, and 1.5 million people currently (2012) suffer from Parkinson disease in the U.S. The large pool of patients that suffer from depression, stroke, anxiety disorders, lower back pain, urinary incontinence, and tremor offers the neuromodulation industry opportunities to grow in the next five years. The market for treatment of tinnitus, in particular, represents an emerging application of neuromodulation. According to the American Tinnitus Association, about 50 million people currently (2012) suffer from this disease in the U.S.

This report estimates the market for six major segments, namely, spinal cord stimulation, deep brain stimulation, sacral nerve stimulation, vagus nerve stimulation, gastric electrical stimulation, transcranial magnetic stimulation, and others. The report also estimates the market for different neuromodulation techniques as well as geographic analysis of each segment in North America, Europe, Asia-Pacific, and Rest of the World. As technologies develop and the number of trained physician increases, the likelihood of neuromodulation being seen as life-changing treatment will increase dramatically. It is estimated that the market for neuromodulation will be shared largely by deep brain stimulation and spinal cord stimulation.

The key players in the neuromodulation market are Medtronic, Inc. (U.S.), Cyberonics, Inc. (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical (U.S.), Enteromedics, Inc (U.S.), Neuropace, Inc (U.S.), Zynex, Inc (U.S.) and Neuronetics, Inc (U.S.). The emerging players in this market are Functional Neuromodulation, Ltd (U.S.), Microtransponder (U.S.), and Neurosigma, Inc (U.S.).

Scope of the Report

The research report categorizes the global neuromodulation market by procedure, technology, and application. These markets are broken down into segments and sub-segments, providing exhaustive value-volume analysis for 2010, 2011, and 2012 as well as forecast up to 2017. Each market is also analyzed by geography (North America, Europe, Asia-Pacific, and Rest of the World to provide in-depth information on the global scenario.

Global Neurostimulation Devices Market, by Procedure:

  • Internal Neurostimulation
    • Spinal Cord Stimulation (SCS)
      • Failed Back Surgery Syndrome
      • Chronic Pain
      • Ischemic Pain
      • Others
    • Deep Brain Stimulation (DBS)
      • Movement Disorders
        • Parkinson’s  Disease 
        • Alzheimer’s Disease
        • Dystonia
        • Tourette’s Syndrome
        • Others
      • Chronic Pain
      • Depression
      • Post-Traumatic Coma
    • Sacral Nerve Stimulation (SNS)
      • Urine Incontinence
      • Fecal Incontinence
    • Vagus Nerve Stimulation (VNS)
      • Epilepsy disease
      • Heart Failure
      • Tinnitus
      • Others
    • Gastric Electrical Stimulation (GES)
      • Gastroparesis
      • Others
  • External Neurostimulation  
    • Transcranial Magnetic Stimulation (TMS)
      • Depression
      • Tinnitus
      • Migraine
      • Stroke
      • Others
    • Transcutaneous Electrical Nerve Stimulation (TENS)

Global Neurostimulation Devices Market, by Geography

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

TABLE OF CONTENTS

1 INTRODUCTION
  1.1 KEY TAKE-AWAYS
  1.2 REPORT DESCRIPTION
  1.3 MARKETS COVERED
  1.4 RESEARCH METHODOLOGY
      1.4.1 MARKET SIZE
      1.4.2 MARKET SHARE
      1.4.3 KEY DATA POINTS FROM SECONDARY SOURCES
      1.4.4 KEY DATA POINTS FROM PRIMARY SOURCES
      1.4.5 ASSUMPTIONS
  1.5 STAKEHOLDERS

2 EXECUTIVE SUMMARY

3 MARKET OVERVIEW
  3.1 INTRODUCTION
  3.2 MARKET SEGMENTATION
  3.3 MARKET DYNAMICS
      3.3.1 DRIVERS
            3.3.1.1 INCREASING INCIDENCE OF NEUROLOGICAL DISORDERS TO SPUR MARKET GROWTH
            3.3.1.2 UNPRECEDENTED GLOBAL AGING TO FUEL MARKET GROWTH
            3.3.1.3 STRONG PRODUCT PIPELINE TO PROPEL THE MARKET
            3.3.1.4 EXPANDED TARGET APPLICATIONS AND NEW INDICATIONS ARE EXPECTED TO STIMULATE GROWTH OF NEUROMODULATION DEVICES
            3.3.1.5 INVESTMENTS AND FUNDS – AN IMPETUS FOR MARKET GROWTH
  3.4 RESTRAINTS
      3.4.1.1 AN UNFAVOURABLE REIMBURSEMENT SCENARIO HINDERS MARKET GROWTH
      3.4.1.2 LACK OF TRAINED PROFESSIONALS LIKELY TO HAMPER MARKET GROWTH
  3.5 MARKET SHARE ANALYSIS

4 GLOBAL NEUROMODULATION MARKET (INTERNAL & EXTERNAL)
  4.1 INTRODUCTION
  4.2 INTERNAL STIMULATION
      4.2.1 SPINAL CORD STIMULATION (SCS) MARKET
            4.2.1.1 MAJOR APPLICATIONS
                    4.2.1.1.1 FAILED BACK SURGERY SYNDROME
                    4.2.1.1.2 CHRONIC PAIN
                    4.2.1.1.3 ISCHEMIA
      4.2.2 DEEP BRAIN STIMULATION (DBS)
            4.2.2.1 MAJOR APPLICATIONS
                    4.2.2.1.1 PARKINSON’S DISEASE
                    4.2.2.1.2 DYSTONIA
                    4.2.2.1.3 TREMOR
                    4.2.2.1.4 ALZHEIMER’S
      4.2.3 SACRAL NERVE STIMULATION (SNS)
            4.2.3.1 MAJOR APPLICATIONS
                    4.2.3.1.1 URINE INCONTINENCE
                    4.2.3.1.2 FECAL INCONTINENCE
      4.2.4 VAGUS NERVE STIMULATION (VNS)
            4.2.4.1 MAJOR APPLICATIONS
                    4.2.4.1.1 EPILEPSY
                    4.2.4.1.2 OTHERS
      4.2.5 GASTRIC ELECTRICAL STIMULATION (GES)
  4.3 EXTERNAL STIMULATION
      4.3.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS)
      4.3.2 TRANSCRANIAL MAGNETIC STIMULATION (TMS)

5 GEOGRAPHIC ANALYSIS
  5.1 INTRODUCTION
  5.2 NORTH AMERICA
  5.3 EUROPE
  5.4 ASIA
  5.5 REST OF THE WORLD

6 COMPETITIVE LANDSCAPE
  6.1 INTRODUCTION
  6.2 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, CONTRACTS & JOINT VENTURES
  6.3 NEW PRODUCT LAUNCH
  6.4 EXPANSION
  6.5 OTHER DEVELOPMENTS
  6.6 APPROVALS

7 COMPANY PROFILES (OVERVIEW, FINANCIALS, PRODUCTS & SERVICES, STRATEGY, & DEVELOPMENTS)*
  7.1 ANM ADAPTIVE NEUROMODULATION GMBH
  7.2 BIOCONTROL MEDICAL, LTD.
  7.3 BOSTON SCIENTIFIC CORPORATION
  7.4 CERBOMED GMBH
  7.5 CYBERONICS, INC.
  7.6 ENDOSTIM, INC.
  7.7 ENTEROMEDICS, INC.
  7.8 THE MAGSTIM COMPANY LIMITED
  7.9 MEDTRONIC, INC.
  7.10 NEURONETICS, INC.
  7.11 NEUROPACE, INC.
  7.12 NEUROSIGMA, INC.
  7.13 NEVRO CORPORATION
  7.14 RS MEDICAL
  7.15 SPINAL MODULATION, INC.
  7.16 ST. JUDE MEDICAL
  7.17 SYNAPSE BIOMEDICAL, INC.
  7.18 UROPLASTY, INC.
  7.19 ZYNEX, INC.
*DETAILS ON FINANCIALS, PRODUCT & SERVICES, STRATEGY, AND DEVELOPMENTS MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.


 
LIST OF TABLES
 
TABLE 1 GLOBAL NEUROMODULATION MARKET, BY PROCEDURE,2010 – 2017 ($MILLION)
TABLE 2 GLOBAL NEUROMODULATION MARKET, BY MODALITY,2010 – 2017 ($MILLION)
TABLE 3 SCS MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION)
TABLE 4 SCS MARKET VOLUME, BY GEOGRAPHY,2010 – 2017 (NO OF UNITS)
TABLE 5 GLOBAL SCS MARKET, BY APPLICATION,2010 – 2017 ($MILLION)
TABLE 6 DBS MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION)
TABLE 7 DBS MARKET VOLUME, BY GEOGRAPHY,2010-2017 (NO OF UNITS)
TABLE 8 GLOBAL DBS MARKET, BY APPLICATION,2010 – 2017 ($MILLION)
TABLE 9 SNS MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION)
TABLE 10 SNS MARKET VOLUME, BY GEOGRAPHY,2010 – 2017 (NO OF UNITS)
TABLE 11 GLOBAL SNS MARKET, BY APPLICATION,2010 – 2017 ($MILLION)
TABLE 12 VNS MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION)
TABLE 13 VNS MARKET VOLUME, BY GEOGRAPHY,2010 – 2017 (NO OF UNITS)
TABLE 14 GLOBAL VNS MARKET, BY APPLICATION,2010 – 2017 ($MILLION)
TABLE 15 GES MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION)
TABLE 16 GES MARKET VOLUME,BY GEOGRAPHY, 2010 – 2017 (NO OF UNITS)
TABLE 17 GLOBAL GES MARKET,BY APPLICATION, 2010-2017 ($MILLION)
TABLE 18 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET,BY GEOGRAPHY, 2010 – 2017($MILLION)
TABLE 19 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET VOLUME, BY GEOGRAPHY, 2010 – 2017 (NO OF UNITS)
TABLE 20 TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 21 TRANSCRANIAL MAGNETIC STIMULATION MARKET VOLUME,BY GEOGRAPHY, 2010 – 2017 (NO OF UNITS)
TABLE 22 GLOBAL TRANSCRANIAL MAGNETIC STIMULATION MARKET,BY APPLICATION, 2010 – 2017 ($MILLION)
TABLE 23 NEUROMODULATION DEVICES MARKET, BY GEOGRAPHY,2010 – 2017 ($MILLION)
TABLE 24 EXTERNAL NEUROMODULATION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 25 INTERNAL NEUROMODULATION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 26 GLOBAL EXTERNAL NEUROMODULATION MARKET, BY MODALITY,2010 – 2017 ($MILLION)
TABLE 27 GLOBAL EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME,BY MODALITY, 2010 – 2017 (NO OF UNITS)
TABLE 28 NORTH AMERICA: NEUROMODULATION DEVICES MARKET,BY PROCEDURE, 2010 – 2017 ($MILLION)
TABLE 29 NORTH AMERICA: INTERNAL NEUROMODULATION DEVICES MARKET, BY MODALITY, 2010 – 2017 ($MILLION)
TABLE 30 NORTH AMERICA: INTERNAL NEUROMODULATION DEVICES MARKET VOLUME, BY MODALITY, 2010 – 2017 (NO. OF UNITS)
TABLE 31 NORTH AMERICA: EXTERNAL NEUROMODULATION DEVICES MARKET, BY MODALITY, 2010 – 2017 ($MILLION)
TABLE 32 NORTH AMERICA: EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME, BY MODALITY, 2010 – 2017 (NO. OF UNITS)
TABLE 33 NORTH AMERICA: SCS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 34 NORTH AMERICA: DBS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 35 NORTH AMERICA: SNS, BY COUNTRY,2010 – 2017 ($MILLION)
TABLE 36 NORTH AMERICA: VNS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 37 NORTH AMERICA: GES MARKET,BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 38 NORTH AMERICA: TMS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 39 NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 40 EUROPE: NEUROMODULATION DEVICES MARKET, BY PROCEDURE,2010 – 2017 ($MILLION)
TABLE 41 EUROPE: INTERNAL NEUROMODULATION DEVICES MARKET,BY MODALITY, 2010 – 2017 ($MILLION)
TABLE 42 EUROPE: INTERNAL NEUROMODULATION DEVICES MARKET VOLUME, BY MODALITY, 2010 – 2017 (NO. OF UNITS)
TABLE 43 EUROPE: EXTERNAL NEUROMODULATION DEVICES MARKET,BY MODALITY, 2010 – 2017 ($MILLION)
TABLE 44 EUROPE: EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME, BY MODALITY, 2010 – 2017 (NO. OF UNITS)
TABLE 45 EUROPE: SCS MARKET, BY REGION,2010 – 2017 ($MILLION)
TABLE 46 EUROPE: DBS, BY REGION,2010 – 2017 ($MILLION)
TABLE 47 EUROPE: SNS, BY REGION,2010 – 2017 ($MILLION)
TABLE 48 EUROPE: VNS MARKET, BY REGION,2010 – 2017 ($MILLION)
TABLE 49 EUROPE: GES MARKET, BY REGION, 2010 – 2017 ($MILLION)
TABLE 50 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET,BY REGION, 2010 – 2017 ($MILLION)
TABLE 51 EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2010 – 2017 ($MILLION)
TABLE 52 ASIA: NEUROMODULATION DEVICES MARKET, BY PROCEDURE,2010 – 2017 ($MILLION)
TABLE 53 ASIA: INTERNAL NEUROMODULATION DEVICES MARKET, BY MODALITY, 2010 – 2017 ($MILLION)
TABLE 54 ASIA: INTERNAL NEUROMODULATION DEVICES MARKET VOLUME,BY MODALITY, 2010 – 2017 (NO. OF UNITS)
TABLE 55 ASIA: EXTERNAL NEUROMODULATION DEVICES MARKET,BY MODALITY, 2010 – 2017 ($MILLION)
TABLE 56 ASIA: EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME,BY MODALITY, 2010 – 2017 (NO. OF UNITS)
TABLE 57 ASIA: SCS MARKET, BY COUNTRY,2010 – 2017 ($MILLION)
TABLE 58 ASIA: DBS MARKET, BY COUNTRY,2010 – 2017 ($MILLION)
TABLE 59 ASIA: SNS, BY COUNTRY,2010 – 2017 ($MILLION)
TABLE 60 ASIA: TMS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 61 ASIA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION)
TABLE 62 ROW: NEUROMODULATION DEVICES MARKET, BY PROCEDURE,2010 – 2017 ($MILLION)
TABLE 63 ROW: INTERNAL NEUROMODULATION DEVICES MARKET, BY MODALITY, 2010 – 2017 ($MILLION)
TABLE 64 ROW: INTERNAL NEUROMODULATION DEVICES MARKET VOLUME,BY MODALITY, 2010 – 2017 (NO. OF UNITS)
TABLE 65 ROW: EXTERNAL NEUROMODULATION DEVICES MARKET,BY MODALITY, 2010 – 2017 ($MILLION)
TABLE 66 ROW: EXTERNAL NEUROMODULATION DEVICES MARKET VOLUME,BY MODALITY, 2010 – 2017 (NO. OF UNITS)
TABLE 67 ROW: SCS MARKET, BY REGION,2010 – 2017 ($MILLION)
TABLE 68 ROW: DBS MARKET, BY REGION,2010 – 2017 ($MILLION)
TABLE 69 ROW: SNS, BY REGION,2010 – 2017 ($MILLION)
TABLE 70 ROW: VNS MARKET, BY REGION,2010 – 2017 ($MILLION)
TABLE 71 ROW: GES MARKET, BY REGION,2010 – 2017 ($MILLION)
TABLE 72 ROW: TRANSCRANIAL MAGNETIC STIMULATION MARKET, BY REGION, 2010 – 2017 ($MILLION)
TABLE 73 ROW: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET, BY REGION, 2010 – 2017 ($MILLION)
TABLE 74 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, CONTRACTS & JOINT VENTURES, 2010 – 2012
TABLE 75 NEW PRODUCT LAUNCH, 2010 – 2012
TABLE 76 EXPANSION, 2010 – 2012
TABLE 77 OTHER DEVELOPMENTS, 2010 – 2012
TABLE 78 APPROVALS, 2010 – 2012
TABLE 79 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)
TABLE 80 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY SEGMENTS, 2009 – 2011 ($MILLION)
TABLE 81 BOSTON SCIENTIFIC: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION)
TABLE 82 CYBERONICS, INC.: TOTAL REVENUE AND R&D EXPENDITURE,2009 – 2011 ($MILLION)
TABLE 83 CYBERONICS, INC.: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION)
TABLE 84 MEDTRONIC, INC.: TOTAL REVENUE AND R&D EXPENDITURE,2009 – 2011 ($MILLION)
TABLE 85 MEDTRONIC, INC: TOTAL REVENUE, BY SEGMENTS,2009 – 2011 ($MILLION)
TABLE 86 MEDTRONIC, INC.: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION)
TABLE 87 ST. JUDE MEDICAL, INC: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)
TABLE 88 ST. JUDE MEDICAL, INC: TOTAL REVENUE, BY SEGMENTS,2009 – 2011 ($MILLION)
TABLE 89 ST. JUDE MEDICAL, INC: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION)
TABLE 90 UROPLASTY, INC.: TOTAL REVENUE AND R&D EXPENDITURE,2010-2012 ($MILLION)
TABLE 91 UROPLASTY, INC.: TOTAL REVENUE, BY GEOGRAPHY,2010 – 2012 ($MILLION)
TABLE 92 ZYNEX, INC.: TOTAL REVENUE AND R&D EXPENDITURE,2009 – 2011 ($MILLION)
TABLE 93 ZYNEX, INC.: TOTAL REVENUE, BY SEGMENTS,2009 – 2011 ($MILLION)
 
 
LIST OF FIGURES
 
FIGURE 1 NEUROMODULATION MARKET SEGMENTATION
FIGURE 2 MARKET DYNAMICS
FIGURE 3 NEUROMODULATION MARKET SHARE ANALYSIS, BY REVENUE, 2011
FIGURE 4 KEY GROWTH STRATEGIES, 2010 – 2012
 

Neuromodulation is considered a promising field of the medical device industry. It originated thousands of years ago with the use of electricity from electric fish to treat pain and other conditions; this medical application gained industrial popularity in the mid-18th century. Revolution in neuromodulation technology began in 1960 with the development of the deep brain stimulation technique, soon followed by spinal cord stimulation.

The concept of neuromodulation is based on the reversible alteration of the nervous system. Being reversible in nature, this technique is safe and has varied applicability as it can be turned off any time in all types of treatments. Neuromodulation involves the use of electrodes implanted at specific places in the brain, spinal cord, and peripheral nerves. These electrodes comprise of leads that are further connected by means of an extension cable to a pulse generator and power source, which generate mild electrical pulses to modulate the specific nerves. Neuromodulation is a safe treatment for people suffering from epilepsy, Parkinson’s, chronic pain, failed back surgery syndrome (FBSS/FBS), heart failure, incontinence, stroke, headache, depression, along with emerging applications for migraine, tinnitus, sleep apnea, spinal cord injury, Alzheimer’s disease, obesity, and others.

The neuromodulation market encompasses a range of technology that is invasive as well as non-invasive. The invasive technology comprises of surgical implantations of the device, further segmented into Spinal Cord Stimulation (SCS), Deep Brain Stimulation (DBS), Sacral Nerve Stimulation (SNS), Vagus Nerve Stimulation (VNS), and Gastric Electrical Stimulation (GES). Non-invasive neuromodulation involves the external application of electrical pulses and magnetic effect, which is divided into Transcranial Magnetic Stimulation (TMS) and Transcutaneous Electrical Nerve Stimulation (TENS). These techniques primarily evolved as treatments for specific disease like Parkinson’s, tremors, and dystonia; however, current clinical research is expected to expand their applications for other serious diseases like Alzheimer’s and depression. SCS is predominantly used to treat chronic pain, SNS is used to treat incontinence, VNS is used to treat epilepsy, and GES deals with gastroparesis.

The neuromodulation market is predicted to expand exponentially in the coming decade, driven by rapid advances in technology and clinical trials, approval of innovative devices, rise in population suffering from age-related disorders, and the presence of a large number of niche companies. The VNS market will show the highest growth, although the SCS market has the highest share of the market.

The neuromodulation market is led by North America, followed by Europe, and Asia-Pacific.

Global Neuromodulation Market Share, By Technology, 2012

Neurostimulation Market

Source: Annual reports, SEC Filings, Press Releases, Investor Presentations, Orthopedic Network News, Expert Opinions, MnM Analysis

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports